#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX
Actinium Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
Allogene Therapeutics' Zachary J Roberts MD PhD explains the elements of #allogeneic #cartcelltherapy that make it an attractive strategy to target relapsed/refractory Chronic lymphocytic leukemia (#CLL) that could also suggest promise in additional scenarios. #cellandgenetherapy #cartcell #cgt 🔗 https://lnkd.in/eYSQAu6M
-
The first patient has been dosed in a first-in-human phase 1 clinical trial (NCT05470140) evaluating Wugen’s WU-NK-101, an investigational allogeneic NK cell therapy, for the treatment of acute myeloid leukemia. #leusm https://ow.ly/kgvj50PC5E4
-
Could your patients be eligible for the KOMET-008 clinical trial aimed at evaluating ziftomenib, a menin inhibitor, with other existing standard-of-care treatments in relapsed or refractory acute myeloid leukemia? Hematologist-oncologist Harry Erba, MD, PhD, explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007. KOMET-008 is OPENING SOON. Learn more: https://lnkd.in/g37mAZZq
-
How can CAR-T therapy be applied to new cancer types? In a recent paper, researchers analyzed RNA-Seq data for novel, safe targets to treat acute myeloid leukemia (AML). Read more on today's blog: https://ow.ly/E6LX50PIeTE #RNA-seq #bioinformatics #CARTherapy
-
-
Today’s blog unlocks a few secrets of how single cell RNA-sequencing data is directing the benefits of CAR-T therapy toward acute myeloid leukemia! Read more to learn about the Nature study that reveals new hope in our battle against this challenging disease. #cartcelltherapy #leukemia
How can CAR-T therapy be applied to new cancer types? In a recent paper, researchers analyzed RNA-Seq data for novel, safe targets to treat acute myeloid leukemia (AML). Read more on today's blog: https://ow.ly/E6LX50PIeTE #RNA-seq #bioinformatics #CARTherapy
-
-
The first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia (AML) at MD Anderson has received treatment with CHM 0201 in combination with Azacitidine and Venetoclax: https://buff.ly/4buckRV #biotech #celltherapy ADVENT-AML is the first clinical trial to evaluate NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia (AML) patients.
-
-
ICYMI: How can CAR-T therapy be applied to new cancer types? In a recent paper, researchers analyzed RNA-Seq data for novel, safe targets to treat acute myeloid leukemia (AML). Read more on BI's blog: https://ow.ly/E6LX50PIeTE #RNA-seq #bioinformatics #CARTherapy #bridgeinformatics
-
-
To test remission in acute promyelocytic leukemia (#APL), the quantification of PML::RARA fusion transcripts of translocation is key. Could a single multiplex RT-qPCR assay provide accurate answers in <5hrs? How does it compare to existing tests? Check out the results. https://bit.ly/3Rj6c5S
-
-
In highly pretreated leukemia, a small molecule inhibitor of the menin–KMT2A interaction, revumenib, provided impressive rates of response. https://lnkd.in/giuPvHZP
-
-
We constantly ask what we at Pixelgen can enable our customers to do and empower their research studies. Listen to our webinar with Dr. Jessica Nordlund to learn about Mapping ex vivo drug responses in B cell leukemia and the role of MPX in it. https://lnkd.in/dc-9Tm7K #TestimonialTuesday #MolecularPixelation #MPX #spatialproteomics #proteins #Pixelation #Pixelator
-
Biotech Oncology Commercial Exec, Radiopharmaceuticals, Marketing, Thought Leader, Sales, & Training Expertise. 5 Oncology launches
1moWonderful news from Actinium Pharmaceuticals, Inc. My wife and I lost a dear family friend to AML. He was a 10 year survivor of metastatic bladder cancer. He was a CR and cancer free after a entering a Pfizer PD-1 clinical trial at Cleveland Clinic. Unfortunately he developed a secondary malignancy (AML) after 1L gem/cis. Hopeful your research leads to amazing results for AML patients.